Pacer Data & Infra Real Estate ETF vs Viatris Inc — how do they compare? Pacer Data & Infra Real Estate ETF trades at $28.24 (market cap $301.85M), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Viatris Inc is far larger — about 66.7× Pacer Data & Infra Real Estate ETF's market cap, and Viatris Inc pays a 2.74% dividend while Pacer Data & Infra Real Estate ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pacer Data & Infra Real Estate ETF for 10 Days and Viatris Inc for 57 Days on average.
| SRVR | VTRS | |
|---|---|---|
Market Cap | $301.85M | $20.12B |
Volume | 119,106 | 7,543,511 |
Sector | Sector/Thematic | Health |
52-Week High | $35.74 | $18.27 |
52-Week Low | $28.17 | $9.74 |
Typical Hold Time | 10 Days | 57 Days |
Enterprise Value | — | $32.24B |
Dividend Yield | — | 2.74% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Pacer Data & Infra Real Estate ETF seeks exposure to real estate companies that own digital infrastructure assets. Its holdings may include data centers, cell towers, fiber networks, and other connectivity-related real estate.
Read more on SRVR →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →